ARDELYX, INC. Restructuring Charges
ARDELYX, INC. (ARDX) reported Restructuring Charges of $0 for the 3-month period ending 2022-09-30, per its 10-Q filed 2022-11-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-02-22
- ARDELYX, INC. restructuring charges for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- ARDELYX, INC. restructuring charges for the quarter ending 2021-12-31 was $2.60M.
- ARDELYX, INC. restructuring charges for the quarter ending 2021-09-30 was $3.60M.
- ARDELYX, INC. restructuring charges for fiscal 2021 was $6.20M.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2022-09-30 | $0.00 10-Q · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $6.20M derived: sum of 2 quarters · filed 2024-02-22 | $6.20M 10-K · filed 2024-02-22 | |
| 2021-09-30 | $3.60M 10-Q · filed 2022-11-03 | $3.60M 10-Q · filed 2022-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |